摘要
目的:探讨阿立派唑治疗精神分裂症对患者认知功能和神经营养因子(NT)的影响。方法:选取2019年9月至2020年6月在商丘市第二人民医院治疗的75例精神分裂症患者,随机抽签分为对照组(38例)与观察组(37例)。对照组口服利培酮,观察组使用阿立派唑片治疗,比较两组治疗前后精神分裂症认知功能成套测验(MCCB)评分及血清神经营养因子(NT)水平。结果:治疗前两组患者的MCCB各项评分及总分差异无统计学意义(P>0.05),治疗后观察组除持续操作测验、符号编码外的MCCB各项评分及总分较对照组显著增大(P<0.05);治疗前两组患者血清神经营养因子-3(NT-3)、神经生长因子(NGF)、脑源神经营养因子(BDNF)的水平差异无统计学意义(P>0.05),治疗后观察组NT-3、NGF、BDNF的水平显著高于对照组(P<0.05)。结论:阿立派唑治疗精神分裂症可上调患者NT水平,使受损的认知功能得到改善。
Objective:To explore the effects of aripiprazole on cognitive function and neurotrophic factor(NT)in patients with schizophrenia.Methods:75 patients with schizophrenia who were treated in Shangqiu Second People's Hospital from September 2019 to June 2020 were selected and randomly divided into control group(38 cases)and observation group(37 cases).The control group was treated with risperidone,and the observation group was treated with aripiprazole.The scores of measurement and treatment research to improve cognition in Schizophrenia consensus cognitive battery(MCCB)and serum level of NT before and after treatment were compared between the two groups.Results:Before treatment,there was no significant difference in MCCB scores between the two groups(P>0.05),and after treatment,the MCCB scores and total scores of the observation group were significantly higher than those of the control group except the continuous operation test and symbol coding(P<0.05).There were no significant differences in serum levels of neurotrophic factor-3(NT-3),nerve growth factor(NGF)and brain-derived neurotrophic factor(BDNF)between the two groups before treatment(P>0.05),and after treatment,the levels of serum NT-3、NGF、BDNF in the observation group were significantly higher than those of the control group(P<0.05).Conclusion:Aripiprazole in the treatment of schizophrenia can up-regulate the NT level of patients and improve the impaired cognitive function.
作者
田玉霞
TIAN Yuxia(Shangqiu Second People's Hospital,Shangqiu Henan 476000,China.)
出处
《药品评价》
CAS
2021年第5期315-317,共3页
Drug Evaluation
